Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.āāā ā
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
$1.04
Price-0.01%
$0.00
$24.799m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-
3y CAGR-
5y CAGR-$13.098m
-
1y CAGR-
3y CAGR-
5y CAGR-$0.60
-
1y CAGR-
3y CAGR-
5y CAGR$19.054m
$22.598m
Assets$3.544m
Liabilities$480k
Debt2.1%
-
Debt to EBITDA-$12.640m
-
1y CAGR-
3y CAGR-
5y CAGR